Companies / Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

Nasdaq: NTLACIK 1652130CAMBRIDGE, MAintelliatx.com ↗

Financials · FY2025

Revenue$67.67M
Net income$-412.69M
Total debt—
Cash$106.13M
Diluted EPS$-3.81
Shares outstanding140.1M

Ownership

140.1M shares outstanding · as of Jul 31, 2026
1.5%Insiders
Ownership
Insiders1.52%2,136,465
10%+ / strategic16.38%22,959,468
Institutions69.10%96,833,109
Public float12.99%18,197,651

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 8

View all →
Insider% of sharesShares
Leonard John MCEOPresident and CEO · Director
0.83%1,169,739
Cohen Fred EDirector
0.15%216,653
Dulac Edward J IIIEVP, Chief Financial Officer
0.11%160,963
Basta JamesEVP, General Counsel
0.11%156,794
Schultes Birgit CEVP, Chief Scientific Officer
0.10%137,733
Lebwohl DavidEVP, Chief Medical Officer
0.09%131,192
Clark ElianaEVP, Chief Technical Officer
0.07%93,864
Dube Michael PVP, Chief Accounting Officer
0.05%69,527

Institutional holders 304

View all →
HolderValue% of shares
BlackRock, Inc.$260.72M11.00%
State Street Corporation$156.26M6.59%
ARK Investment Management LLC$127.72M10.14%
Vanguard Group Inc$116.96M9.28%
D. E. Shaw & Co., Inc.$73.44M4.09%
Regeneron Pharmaceuticals, Inc.$62.65M2.64%
Two Sigma Investments, LP$60.33M3.36%
Geode Capital Management, LLC$36.56M2.03%
Jupiter Asset Management Ltd$22.83M1.27%
Two Sigma Advisers, LP$21.09M1.67%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 5, 2026Cohen Fred E
Director
BuyCommon Stock$1.40M+150K
+261.08%
207,453
0.15% of shares
high
Jan 5, 2026Leonard John M
CEO
SellCommon Stock$314.5K-34K
-3.26%
1,013,339
0.72% of shares
medium
Jan 5, 2026Lebwohl David
Executive
SellCommon Stock$109.6K-12K
-8.94%
121,249
0.09% of shares
medium
Jan 5, 2026Basta James
Executive
SellCommon Stock$95.8K-10K
-9.29%
101,528
0.07% of shares
low
Jan 5, 2026Clark Eliana
Executive
SellCommon Stock$87.6K-10K
-9.85%
87,118
0.06% of shares
low
Jan 5, 2026Schultes Birgit C
Executive
SellCommon Stock$78.4K-9K
-7.95%
98,533
0.07% of shares
low
Jan 5, 2026Dulac Edward J III
Executive
SellCommon Stock$58.8K-6K
-6.01%
99,683
0.07% of shares
low
Jan 5, 2026Dube Michael P
Executive
SellCommon Stock$27.5K-3K
-5.41%
52,277
0.04% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—13,010,001—
State Street CorporationPassive13G—9,234,987—
Vanguard Group IncPassive13G/A—0—
Contrarius Investment Management LtdPassive13G/A—714,480—
ARK Investment Management LLCPassive13G/A———
The Goldman Sachs Group, Inc.Passive13G/A———
State Street CorporationPassive13G—6,418,836—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
NTLA——45826J105—